NCT07404202Recruiting
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Pan HER2: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This is a multicenter, non-interventional, descriptive study to retrospectively collect solid tumor samples from focused tumor types (NSCLC, GYN cancers, BTC and UC) and assess both assay concordance and interpretation concordance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2100 (estimated)
- First submitted
- 5 Feb 2026
- Start date
- 6 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Childhood cancers
- NCT number
- NCT07404202
What you commit to
- Study type: Observational
- Planned participants: 2100
- From 6 Mar 2026 to the primary completion date, 31 Dec 2026
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Have a history of other cancers besides NSCLC, BTC, GYN cancers and UC.
Other
- 2\. Specimens of patients that may affect interpretation evaluated by the researcher (e.g., frozen specimens, decalcified specimens, specimens with limited tumor content, etc.)
Who the study is looking for
- 1\. Patients must be at least 18 years of age
- 2\. Male and female patients must have a histological confirmed diagnosis of NSCLC, BTC, GYN cancers, or UC between Jan 01, 2023 and Sep 30, 2025.
- --For GYN cancers, only cervical cancer, endometrial cancer and ovarian cancer should be included. For each gynecological cancer listed above, at least 5 cases need to be enrolled at each expression level (i.e., IHC 0/1+/2+/3+).
- 3\. Patients must have sufficient archived tumor tissue available, with at least 15 slides suitable for HER2 status determination. Both resection or biopsy samples are acceptable. The age limit of archived tissue blocks is 5 years.
Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Research Site Coordinator of this site? Confirm its status | Changsha | China | Withdrawn |
| Research Site Coordinator of this site? Confirm its status | Chengdu | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Guangzhou | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Haerbin | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Jinan | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Nantong | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Shanghai | China | Withdrawn |
| Research Site Coordinator of this site? Confirm its status | Shenyang | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Suzhou | China | Withdrawn |
| Research Site Coordinator of this site? Confirm its status | Ürümqi | China | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Zhejiang | China | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.